It might not be possible to use questionnaires like these in the context of an illness. For example, patients receiving steroids, which have the potential to interfere with neuropsychological instruments, might be a problem.
Targeted therapy is used in a variety of adult and pediatric leukemia cases. Common forms of targeted therapy include tyrosine kinase inhibitors and anthracycline or platinum-based drugs. More advanced cases may involve more advanced drug regimens or combination therapy.
Patients with chronic myeloid leukemia will probably be cured if they have a complete remission of the disease. However, patients with B-cell precursors of acute myelogenous leukemia will not be cured, since relapse will probably occur. Patients with acute myelogenous leukemia, a subtype of B-cell precursors, may be affected (relapse) if they do not receive treatment. The effect of cancer therapies on chronic myelogenous leukemia remains uncertain.
Signs of leukemia appear similar in each leukemia subtype and all patients are at increased risk because all cases may contain only one sign of leukemia. If the signs of leukemia are not present, other symptoms such as fatigue, unintentional weight loss, fever, malaise, and dizziness should be followed up in order to find signs of leukemia and monitor patient response to treatment.
leukemias and other cancers share some of the same inherited predisposition and risk factors. The occurrence of leukemias may be influenced in part by environmental factors including the use of carcinogens or viral infection. Other risk factors include an underlying genetic defect like familial leukemia, and environmental exposures to ionizing radiation and chemicals.
Around 20,300 cases of acute myeloid leukemia (AML) and 1,400 cases of acute lymphocytic leukemia (ALL) occur each year in adults. For children, AML accounted for 20,300 cases and ALL for 1,240 cases.
Leukemia is a type of cancer that forms in the white blood cells, the bone marrow and the platelets, and is caused by abnormal cells arising from the hematopoietic stem cells in the bone marrow and blood. It is sometimes fatal and frequently arises from leukemic genes.
No breakthroughs in treatment have been found in all aspects of leukemia since 1960. Many drugs have come into use and shown promise in the treatment of acute leukemia. The development of targeted and personalized therapies for leukemias have shown promise in the treatment of chronic myeloid leukemia, whereas the first new drug for the treatment of acute lymphoblastic leukaemia for many years is lenalidomide. There have been some advances in treatment. For patients with chronic myeloid leukaemia, and chronic lymphocytic leukaemia, the treatment of choice has been consolidation therapy, combining several drugs with different mechanisms of action on different blood cell types.
There seem to be two distinct areas of methodological quality in medical research. There is either an absence or an inadequate number of trials that actually use questionnaires to evaluate participants, or alternatively the methodology can be described as poor. We consider that the questionnaire should be used in further clinical studies, especially the quality of life assessment, in cancer care. One should consider the use of the Quality of Life Questionnaire in clinical trials so as to help to evaluate the quality of care.
When a person is diagnosed with leukemia, the risk of secondary cancer is approximately one-third. It is difficult to definitively make an honest estimation of the risk, as this depends on many factors, including age at diagnosis, sex, type of diagnosis, lifestyle, and time interval between diagnoses of leukemia and second cancers.\n
It is very likely that a high proportion of leukemia cases has an inherited genetic component. Inherited cancer predisposition may be attributable to mutated DNA, or it may in turn be due to environmental risk factors, such as lifestyle. Genetic predisposition may be more pronounced than environmental risk factors in sporadic or juvenile forms of leukemia.